Renata Ferrarotto, MD, discusses the biologic rationale for and interim findings from a phase 1 study of Emi-Le in patients with aggressive ACC.
Renata Ferrarotto
Advertisement
Articles by Renata Ferrarotto
Renata Ferrarotto, MD, discusses the mechanism of action of trilaciclib in extensive-stage small cell lung cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for PSMA+ mHSPC
2
European Commission Approves First-Line Dato-DXd for Immunotherapy-Ineligible Metastatic TNBC
3
FDA sNDA Submission Is Planned for Selinexor Plus Ruxolitinib in Myelofibrosis
4
Baseline and On-Treatment QOL Improvements Track With Survival Benefits With Belzutifan or Everolimus in ccRCC
5